Below is a summary of activities of this section from July 1, 2025 through June 30, 2026. While past activity is no guarantee of future activity, it may give a idea of what to expect this year.
Section Stats
Newsletters
Issues: 2
CLE
Live Programs: 1
Legislation
Bills Reviewed: 144
Continuing Legal Education
Section members receive discounts on section-sponsored CLE programs. During the 2025–26 bar year, the Section sponsored the following programs:
- Co-Sponsor Fundamentals of AI Implementation (during ISBA’s Annual Meeting) (06/12/2026)
ISBA Central Discussions
ISBA Central communities allows section members to pose questions, answer questions, and share information with fellow section members. Members of the section get free access to the section’s community. Joining any section also grants you access to the Transactional and Litigation communities. Below are the total number of discussion posts during the 2025–26 bar year.
Privacy and Information Security Law
- Community members: 281
- Total discussion posts: 0
Transactional
- Community members: 24,715
- Total discussion posts: 386
Litigation
- Community members: 24,710
- Total discussion posts: 706
Legislation
The Section Council reviewed 144 bills that may affect their members’ practice area. Highlights of the most recent legislative session include:
- House Bill 4538 would create the “Identity Verification for Consumer Services Act” to reduce identity theft by requiring entities engaging in certain high-risk or covered service transactions to verify a person’s identity using specified authentication methods before initiating or modifying services. The bill also establishes enforcement under Illinois consumer fraud law but did not become law.
- House Bill 5511 creates the Children’s Social Media Safety Act, establishing new requirements for device manufacturers and online platforms to support age verification for child users. Effective date: January 1, 2028.
- Senate Bill 2886 amends the Genetic Information Privacy Act to extend its confidentiality and use restrictions to biomarker testing information, in addition to genetic testing information. It limits insurers’ use of such information for nontherapeutic or underwriting purposes and restricts how employers and other entities may use or disclose the information, while strengthening protections against unauthorized disclosure of testing results and identities.